JAN 07, 2020 1:53 PM PST

"Good" T Cells Can Go "Bad," But in the Case of Cancer, That's A Good Thing

WRITTEN BY: Kara Marker

T cells may be able to reach their full potential in the fight against cancer with a little nudge. In 2010, scientists first observed CD4+ T cells transitioning from a regulatory role to a cytotoxic role, directly targeting and killing cancer cells as a result of immunotherapy. After this observation, the same team sought to identify the key mechanisms behind this transition. What molecular and cellular interactions are necessary to “nudge” CD4+ T cells in a more cytotoxic direction when survival against cancer is on the line?

T cells like CD4+ cells are included as ingredients in immunotherapy protocols because of their role in the immune response to threats against the body, including cancer and pathogens. Immunotherapy is an approach to cancer treatment that relies on boosting the body’s natural mechanisms for thwarting cancer, including optimizing the activity of immune system components like T cells. To reach their full potential, some T cells first need be equipped to recognize cells as cancerous when necessary.

A new study conducted in mice identified T cell growth factor interleukin (IL)-2 and transcription factor Blimp-1 as factors responsible for altering CD4+ T cells’ functional identity, triggering the change from regulatory to cytotoxic in the context of cancer.

Past research of IL-2 associates this growth factor with working alongside regulatory T cells to maintain self-tolerance, the immune practice of preventing immune cells from attacking the body’s own cells during the immune response. Blimp-1, also know as “B lymphocyte-induced maturation protein-1,” is linked to the “development and function of antibody-producing B cells,” an important part of the adaptive immune response.

With this information, researchers can optimize the way in which they recruit CD4+ T cells in immunotherapy approaches to treat cancer. Upon translating the results of the current study to cases of human immune interactions, researchers can develop novel custom cell therapies specifically targeting IL-2 and Blimp-1 in different contexts of cancer. Results from the present study have the potential to greatly improve the way scientists equip T cells to recognize cancerous cells for application of immunotherapy.

Sources: National Cancer Institute, Journal of Leukocyte Biology, University College London, Immunity

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 19, 2020
Cell & Molecular Biology
Mild COVID-19 Cases Induce an Immune Cell Response
AUG 19, 2020
Mild COVID-19 Cases Induce an Immune Cell Response
As the pandemic virus, SARS-CoV-2 continues to cause tens of thousands of new cases of COVID-19 every day in the United ...
AUG 21, 2020
Microbiology
Vaccine Aimed at Fungi May Also Protect Against MRSA
AUG 21, 2020
Vaccine Aimed at Fungi May Also Protect Against MRSA
Staphylococcus aureus is a common bacterium. If it stays on the skin it's harmless, but if it gets into the bloodstream, ...
SEP 08, 2020
Immunology
Regular Opioid Users Are More Sensitive to Pain, Immune System to Blame
SEP 08, 2020
Regular Opioid Users Are More Sensitive to Pain, Immune System to Blame
Opioids are painkillers such as oxycodone (OxyContin and Percocet) and hydrocodone (Vicodin) that are synthesized to mim ...
OCT 29, 2020
Cell & Molecular Biology
How Does the Immune System Handle the Microbiome?
OCT 29, 2020
How Does the Immune System Handle the Microbiome?
The human body plays host to trillions of microbes, and many of them live in our gastrointestinal tract; these microorga ...
NOV 09, 2020
Drug Discovery & Development
COVID-19 Vaccine by Pfizer More than 90% Effective
NOV 09, 2020
COVID-19 Vaccine by Pfizer More than 90% Effective
A preliminary analysis of Pfizer and BioNTech's COVID-19 vaccine shows that it can prevent over 90% of people from c ...
NOV 12, 2020
Immunology
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
NOV 12, 2020
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
Nutrition is essential to health; what we eat in our daily diet affects our overall health condition and what diseases w ...
Loading Comments...